New research confirms Lutetium-177-PSMA-617 is effective for advanced prostate cancer, even after Radium-223 treatment.

The "Lutetium Oxide (CAS 12032-20-1) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.This report on ...

Lutetium-177 (Lu-177) Market is Segmented by Type (Non-carrier-added, Carrier-added), by Application (Nuclear Therapy, Others). The Lutetium-177 market is poised for significant expansion as ...

What's the story of our Moon's early history? Despite all we know about our closest natural satellite, scientists are still ...

Real-world data support trial data on the use of lutetium-177 PSMA-617 in patients with PSMA-positive, metastatic castration-resistant prostate cancer.

In this video, Tanya Dorff, MD discusses the current state of the pipeline for developing castration-resistant prostate cancer treatments.

Baseline fracture risk for prostate cancer patients initiating long-term androgen deprivation therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

Characterization of circulating tumor DNA (ctDNA) burden and its association with real-world overall survival among prostate cancer (PC) patients. Cancer-control outcomes of metastatic castration ...

Swiss pharma giant Novartis is taking legal action against the Australian cancer care provider as a dispute over how to fund ...

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.